Sanofi ((SNYNF)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Sanofi is conducting a Phase 2a clinical study titled ‘A 52-week Randomized, Double-blind, Placebo-controlled, Multi-center Phase 2a Study Assessing Safety and Efficacy of SAR442970, a Dual Anti-TNF-α and Anti-OX40L NANOBODY® Molecule, for Preservation of Pancreatic β-cell Function in Adults and Adolescents With Recently Diagnosed Type 1 Diabetes.’ The study aims to evaluate the safety and efficacy of SAR442970 in preserving pancreatic β-cell function in individuals recently diagnosed with type 1 diabetes.
The intervention being tested is SAR442970, a dual-action drug designed to target both TNF-α and OX40L, administered via subcutaneous injection. Its purpose is to preserve β-cell function in type 1 diabetes patients.
This study is interventional, randomized, and follows a parallel assignment model. It employs quadruple masking, meaning that participants, care providers, investigators, and outcomes assessors are blinded to the treatment allocation. The primary goal is treatment-focused.
The study began on January 31, 2025, with the most recent update submitted on August 21, 2025. These dates are crucial as they indicate the study’s progress and current status, which is actively recruiting participants.
Sanofi’s update on this study could influence its stock performance by boosting investor confidence in its innovative diabetes treatment pipeline. As the company competes in a crowded market, successful outcomes could enhance its competitive edge and market share.
The study is ongoing, with further details available on the ClinicalTrials portal.